Maze Therapeutics Secures $115 Million Series D Funding to Advance Clinical-Stage Kidney Disease Programs

Maze Therapeutics, Series D funding, kidney disease, clinical-stage programs, precision medicine, APOL1 kidney disease, chronic kidney disease, MZE829, MZE782.